Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.
NCT05931484 · Forest Hills Lab · PHASE2 · withdrawn · last registry update 2026-08-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Has yet to begin and may not so halting to avoid participant outreach” | – | Registry record, Forest Hills Lab |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Results posted on the registry: Alessandro Doria, Fenofibrate (NCT04929379)
- 2026-09-21Results posted on the registry: The Lowy Medical Research Institute Limited, Fenofibrate (NCT04907084)
- 2026-08-19Also stopped (withdrawn): Polaryx Therapeutics, Inc., PLX-200 + Placebo (NCT04637282)
- 2026-07-16Results posted on the registry: Intercept Pharmaceuticals, Bezafibrate 100 mg + Bezafibrate 200 mg (NCT05239468)
- 2026-07-16Results posted on the registry: Intercept Pharmaceuticals, Obeticholic acid + Bezafibrate 200 MG (NCT04594694)
- 2026-07-16Also stopped (terminated): Intercept Pharmaceuticals, Obeticholic acid + Bezafibrate 200 MG (NCT04594694)
- 2026-06-08Results posted on the registry: Intercept Pharmaceuticals, FDC tablet (OCA 5 mg + BZF 400 mg SR) (NCT06488911)
- 2026-06-08Also stopped (terminated): Intercept Pharmaceuticals, FDC tablet (OCA 5 mg + BZF 400 mg SR) (NCT06488911)
- 2026-02-20Phase 3 first posted: Zydus Therapeutics Inc., Saroglitazar Magnesium 1 mg + Placebo (NCT07424677)
- 2026-02-04Phase 3 first posted: Ipsen, Elafibranor (NCT07387549)
- 2025-12-22Phase 3 first posted: Xijing Hospital of Digestive Diseases, Fenofibrate + UDCA (Ursodeoxycholic acid) (NCT07296458)
- 2025-12-18Results posted on the registry: Zydus Therapeutics Inc., Saroglitazar Magnesium 4 mg Tablet + Placebo (NCT03617263)
- 2025-12-18Also stopped (terminated): Zydus Therapeutics Inc., Saroglitazar Magnesium 4 mg Tablet + Placebo (NCT03617263)
- 2025-10-22Results posted on the registry: Mayo Clinic, Fenofibrate (NCT05514119)
- 2025-10-22Also stopped (terminated): Mayo Clinic, Fenofibrate (NCT05514119)
- 2025-10-14Phase 3 first posted: Zydus Therapeutics Inc., Saroglitazar magnesium 1 mg + Placebo (NCT07216235)
- 2025-09-25Results posted on the registry: Kowa Research Institute, Inc., K-877 + Placebo (NCT03071692)
- 2025-09-25Also stopped (terminated): Kowa Research Institute, Inc., K-877 + Placebo (NCT03071692)
- 2025-09-02Also stopped (terminated): Zydus Therapeutics Inc., Saroglitazar Magnesium 4 mg + Placebo (NCT05211284)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision